Multiple sclerosis (MS) can be a challenging disease to diagnose because of its broad range of symptoms and because of the fact that many other syndromes can mimic MS. Additionally, the McDonald Criteria, which are clinical, radiographic, and laboratory criteria used for diagnosing MS, are sometimes misapplied, according to Andrew Solomon, MD, associate professor of neurological sciences and division chief of multiple sclerosis at Larner College of Medicine, The University of Vermont, Burlington, Vermont.
Multiple sclerosis (MS) can be a challenging disease to diagnose because of its broad range of symptoms and because of the fact that many other syndromes can mimic MS. Additionally, the McDonald Criteria, which are clinical, radiographic, and laboratory criteria used for diagnosing MS, are sometimes misapplied, according to Andrew Solomon, MD, associate professor of neurological sciences and division chief of multiple sclerosis at Larner College of Medicine, The University of Vermont, Burlington, Vermont.
Transcript
What are some tips that you gave in your presentation on avoiding misdiagnosis in multiple sclerosis?
In this presentation, because it seems that difficulty with the McDonald Criteria could lead to misdiagnosis, we really emphasized a lot of tips and advice on how to properly use the criteria. There’s a lot of, perhaps, misconceptions about the diagnostic criteria.
Really the most important thing is to first read the document. Read the manuscript, because a lot of times, the diagnostic criteria for MS are reproduced on little cards that don’t have all the caveats for different diagnostic situations. So it’s important to know all the details first.
We emphasized in this session that the first step of making a diagnosis of MS is identifying if a syndrome in a patient that you’re seeing is what we call typical for MS, or an MS-typical syndrome, and that there’s evidence, objective evidence, we call it, of [central nervous system, CNS] involvement. So, corroborating evidence on their neurologic exam or MRI that there’s a lesion responsible for the syndrome. That’s the first step in making a diagnosis of MS.
If the syndrome is atypical, or there’s some red flag, something that’s unusual, you can’t really even apply the McDonald criteria, because it hasn’t been validated in patients like that and would lose its specificity.
So being very familiar with what those syndromes are, which are essentially optic neuritis, myelitis, and some brain stem syndromes, that’s it, and knowing how to verify that there’s objective evidence of those syndromes is a really key skill in making a correct diagnosis.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More